Ebola virus: Current and future perspectives

Infectious Disorders - Drug Targets

Volumn 15, Issue 1, 2015, Pages 20-31

  Jadav, Surender Singh ^a   Kumar, Anoop ^a   Ahsan, Mohamed Jawed ^b   Jayaprakash, Venkatesan ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b Maharisi Arvind College of Pharmacy   (India)

Author keywords

Ebola virus; Pathogenesis; Treatment; Vaccines; vp24 inhibitors

Indexed keywords

AMANTADINE; AMIODARONE; ANTIHYPERTENSIVE AGENT; BRINCIDOFOVIR; CLOMIFENE; EBOLA VACCINE; FAVIPIRAVIR; IMMUCILLIN A; INTERFERON; TOREMIFENE; VIRUS PROTEIN; ANTIVIRUS AGENT;

ANTIMALARIAL ACTIVITY; ARTICLE; CELL MATURATION; DENDRITIC CELL; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY; ZAIRE EBOLAVIRUS; AFRICA; DRUG EFFECTS; EPIDEMIC; GENETICS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; LIBERIA; PATHOGENICITY; VIROLOGY;

AFRICA; ANTIVIRAL AGENTS; EBOLA VACCINES; EBOLAVIRUS; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LIBERIA;

EID: 84930890909     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/1871526515666150320162259     Document Type: Article

References (92)

1. Johnson, K.; Lange, J.; Webb, P.; Murphy, F. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. The Lancet, 1977, 309(8011), 569-571.
2. Baize, S.; Pannetier, D.; Oestereich, L.; Rieger, T.; Koivogui, L.; Magassouba, N. F.; Soropogui, B.; Sow, M. S.; Keita, S.; De Clerck, H. Emergence of Zaire Ebola virus disease in Guinea-preliminary report. N. Engl. J. Med., 2014, 371, 1418-1425.
3. Gatherer, D. The 2014 Ebola virus disease outbreak in west Africa. J. Gen. Virol., 2014, vir. 0. 067199-0.
4. CDC. Centers for Disease Control and Prevention. http://www. cdc. gov/vhf/ebola/(Accessed September 15, 2014).
5. Organization, W. H. Global alert and response: Ebola virus disease(EVD). Geneva, Switzerland. http://www. who. int/csr/don/2014_08_15_ebola/en/(Accessed September 15, 2014).
6. Feldmann, H.; Nichol, S. T.; Klenk, H.-D.; Peters, C. J.; Sanchez, A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology., 1994, 199(2), 469-473.
7. Sullivan, N.; Yang, Z.-Y.; Nabel, G. J. Ebola virus pathogenesis: implications for vaccines and therapies. J. Virol. 2003, 77(18), 9733-9737.
8. Sanchez, A. Ebola Viruses. Wiley Online Library: 2001. DOI: 10. 1038/npg. els. 0001019.
9. Leroy, E. M.; Kumulungui, B.; Pourrut, X.; Rouquet, P.; Hassanin, A.; Yaba, P.; Delicat, A.; Paweska, J. T.; Gonzalez, J.-P.; Swanepoel, R. Fruit bats as reservoirs of Ebola virus. Nature 2005, 438(7068), 575-576.
10. Irving, W. Ebola virus transmission. Int J Clin Exp Pathol, 1995, 76(4), 225.
11. Piot, P.; Bureau, P.; Breman, G.; Heymann, D.; Kintoki, V.; Masamba, M.; Mbuyi, M.; Miatudila, M.; Ruppol, F.; van Nieuwenhove, S. Clinical Aspects Of Ebola Virus Infection In Yambuku Area, Zaire, 1976. Headache, 1978, 210(962), 96-2.
12. Formenty, P.; Hatz, C.; Le Guenno, B.; Stoll, A.; Rogenmoser, P.; Widmer, A. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J. Infect. Dis., 1999, 179(Supplement 1), S48-S53.
13. Jeffs, B. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop Doct, 2006, 36(1), 1-4.
14. Towner, J. S.; Rollin, P. E.; Bausch, D. G.; Sanchez, A.; Crary, S. M.; Vincent, M.; Lee, W. F.; Spiropoulou, C. F.; Ksiazek, T. G.; Lukwiya, M. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J. Virol., 2004, 78(8), 4330-4341.
15. Huggins, J.; Zhang, Z.-X.; Bray, M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J. Infect. Dis., 1999, 179(Supplement 1), S240-S247.
16. Sullivan, N. J.; Sanchez, A.; Rollin, P. E.; Yang, Z.-y.; Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. Nature, 2000, 408(6812), 605-609.
17. Mupapa, K.; Massamba, M.; Kibadi, K.; Kuvula, K.; Bwaka, A.; Kipasa, M.; Colebunders, R.; Muyembe-Tamfum, J. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J. Infect. Dis., 1999, 179(Supplement 1), S18-S23.
18. Du Toit, A. Ebola virus in West Africa. Nature Rev. Microbiol., 2014, 12(5), 312-312.
19. Dixon, M. G.; Schafer, I. J. Ebola Viral Disease Outbreak-West Africa, 2014. MMWR Morb Mortal Wkly Rep, 2014, 63(25), 548-551.
20. Eichner, M.; Dowell, S. F.; Firese, N. Incubation Period of Ebola Hemorrhagic Virus Subtype Zaire. Osong Public Health Res Perspect, 2011, 2(1), 3-7.
21. Goodman, J. L. Studying "Secret Serums"-Toward Safe, Effective Ebola Treatments. N. Engl. J. Med., 2014, 371(12), 1086-1089.
22. Bray, M.; Geisbert, T. W. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell Biol., 2005, 37(8), 1560-1566.
23. Gupta, M.; Mahanty, S.; Ahmed, R.; Rollin, P. E. Monocyte-Derived Human Macrophages and Peripheral Blood Mononuclear Cells Infected with Ebola Virus Secrete MIP-1α and TNF-α and Inhibit Poly-IC-Induced IFN-α in Vitro. Virology, 2001, 284(1), 20-25.
24. Lukashevich, I. S.; Maryankova, R.; Vladyko, A. S.; Nashkevich, N.; Koleda, S.; Djavani, M.; Horejsh, D.; Voitenok, N. N.; Salvato, M. S. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-α gene expression. J. Med. Virol., 1999, 59(4), 552.
25. Schnittler, H.; Feldmann, H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr. Top. Microbiol. Immunol., 1999, 235, 175.
26. Peters, C.; Peters, J. An introduction to Ebola: the virus and the disease. J. Infect. Dis. 1999, 179(Supplement 1), ix-xvi.
27. Cormick, J. B.; King, I. J.; Webb, P. A.; Scribner, C. L.; Craven, R. B.; Johnson, K. M.; Elliott, L. H.; Belmont-Williams, R. Lassa fever. N. Engl. J. Med., 1986, 314(1), 20-26.
28. Villinger, F.; Rollin, P. E.; Brar, S. S.; Chikkala, N. F.; Winter, J.; Sundstrom, J. B.; Zaki, S. R.; Swanepoel, R.; Ansari, A. A.; Peters, C. J. Markedly elevated levels of interferon(IFN)-γ, IFN-α, interleukin(IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection. J. Infect. Dis., 1999, 179(Supplement 1), S188-S191.
29. Mahanty, S.; Hutchinson, K.; Agarwal, S.; Mcrae, M.; Rollin, P. E.; Pulendran, B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J. Immunol., 2003, 170(6), 2797-2801.
30. Hutchinson, K. L.; Villinger, F.; Miranda, M. E.; Ksiazek, T. G.; Peters, C.; Rollin, P. E. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus(reston serotype). J. Med. Virol., 2001, 65(3), 561-566.
31. Fisher-Hoch, S.; McCormick, J. Pathophysiology and treatment of Lassa fever. In Arenaviruses, Springer: 1987; pp 231-239.
32. Bell, D.; Young, J. W.; Banchereau, J. Dendritic cells. Adv. Immunol. 1999, 72, 255-324.
33. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature, 1998, 392(6673), 245-252.
34. Geisbert, T. W.; Hensley, L. E.; Larsen, T.; Young, H. A.; Reed, D. S.; Geisbert, J. B.; Scott, D. P.; Kagan, E.; Jahrling, P. B.; Davis, K. J. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol., 2003, 163(6), 2347-2370.
35. Neil, S. J.; Sandrin, V.; Sundquist, W. I.; Bieniasz, P. D. An interferon-α-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe, 2007, 2(3), 193-203.
36. Basler, C. F.; Wang, X.; Muhlberger, E.; Volchkov, V.; Paragas, J.; Klenk, H.-D.; Garcia-Sastre, A.; Palese, P. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(22), 12289-12294.
37. Hoenen, T.; Groseth, A.; Kolesnikova, L.; Theriault, S.; Ebihara, H.; Hartlieb, B.; Bamberg, S.; Feldmann, H.; Stroher, U.; Becker, S. Infection of naive target cells with virus-like particles: implications for the function of Ebola virus VP24. J. Virol., 2006, 80(14), 7260-7264.
38. Sanchez, A.; Kiley, M. P.; Holloway, B. P.; Auperin, D. D. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus research, 1993, 29(3), 215-240.
39. Feldmann, H.; Klenk, H.-D.; Sanchez, A. Molecular biology and evolution of filoviruses. Springer: Arch Virol, 1993, 7(Supplement 1), 81-100.
40. Huang, Y.; Xu, L.; Sun, Y.; Nabel, G. J. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Molecular cell, 2002, 10(2), 307-316.
41. Oda, T.; Watanabe, S.; Sagara, H.; Kawaoka, Y. Mapping of the VP40-binding regions of the nucleoprotein of Ebola virus. J. Virol., 2007, 81(7), 3554-3562.
42. Basler, C. F.; Mikulasova, A.; Martinez-Sobrido, L.; Paragas, J.; Muhlberger, E.; Bray, M.; Klenk, H.-D.; Palese, P.; Garcia-Sastre, A. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol., 2003, 77(14), 7945-7956.
43. Enterlein, S.; Warfield, K. L.; Swenson, D. L.; Stein, D. A.; Smith, J. L.; Gamble, C. S.; Kroeker, A. D.; Iversen, P. L.; Bavari, S.; Muhlberger, E. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother., 2006, 50(3), 84-993.
44. Prins, K. C.; Cardenas, W. B.; Basler, C. F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKε and TBK-1. J. Virol., 2009, 83(7), 3069-3077.
45. Brown, C. S.; Lee, M. S.; Leung, D. W.; Wang, T.; Xu, W.; Luthra, P.; Anantpadma, M.; Shabman, R. S.; Melito, L. M.; MacMillan, K. S. In Silico Derived Small Molecules Bind the Filovirus VP35 Protein and Inhibit Its Polymerase Cofactor Activity. J. Mol. Biol., 2014, 426(10), 2045-2058.
46. Johnson, R. F.; Bell, P.; Harty, R. N. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J, 2006, 31(3), 1-7.
47. ang, Z.-y.; Duckers, H. J.; Sullivan, N. J.; Sanchez, A.; Nabel, E. G.; Nabel, G. J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med., 2000, 6(8), 886-889.
48. Wahl-Jensen, V.; Kurz, S. K.; Hazelton, P. R.; Schnittler, H.-J.; Stroher, U.; Burton, D. R.; Feldmann, H. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J. Virol., 2005, 79(4), 2413-2419.
49. Marzi, A.; Akhavan, A.; Simmons, G.; Gramberg, T.; Hofmann, H.; Bates, P.; Lingappa, V. R.; Pohlmann, S. The signal peptide of the ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR. J. Virol., 2006, 80(13), 6305-6317.
50. Malashkevich, V. N.; Schneider, B. J.; McNally, M. L.; Milhollen, M. A.; Pang, J. X.; Kim, P. S. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1. 9-A resolution. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(6), 2662-2667.
51. Bhattacharyya, S.; Warfield, K. L.; Ruthel, G.; Bavari, S.; Aman, M. J.; Hope, T. J. Ebola virus uses clathrin-mediated endocytosis as an entry pathway. Virology, 2010, 401(1), 18-28.
52. Weik, M.; Modrof, J.; Klenk, H.-D.; Becker, S.; Muhlberger, E. Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J. Virol., 2002, 76(17), 8532-8539.
53. Han, Z.; Boshra, H.; Sunyer, J. O.; Zwiers, S. H.; Paragas, J.; Harty, R. N. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol., 2003, 77(3), 1793-1800.
54. Licata, J. M.; Johnson, R. F.; Han, Z.; Harty, R. N. Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol., 2004, 78(14), 7344-7351.
55. Volchkov, V. E.; Volchkova, V. A.; Chepurnov, A. A.; Blinov, V. M.; Dolnik, O.; Netesov, S. V.; Feldmann, H. Characterization of the L gene and 5'trailer region of Ebola virus. J. Gen. Virol., 1999, 80(2), 355-362.
56. Krug, R. M. Viral Proteins That Bind Double-Stranded RNA: Countermeasures Against Host Antiviral Responses. J. Interferon Cytokine Res., 2014, 34(6), 464-468.
57. Saphire, E. O.; Bornholdt, Z. A.; Abelson, D. M.; Halfmann, P.; Noda, T.; Wood, M.; Kawaoka, Y. Structural Rearrangement of the Ebola Virus VP40 Protein Begets Multiple Functions in the Virus Life Cycle. Biophys. J., 2014, 106(2), 637a.
58. Hartlieb, B.; Muziol, T.; Weissenhorn, W.; Becker, S. Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(2), 624-629.
59. Basu, A.; Li, B.; Mills, D. M.; Panchal, R. G.; Cardinale, S. C.; Butler, M. M.; Peet, N. P.; Majgier-Baranowska, H.; Williams, J. D.; Patel, I. Identification of a small-molecule entry inhibitor for filoviruses. J. Virol., 2011, 85(7), 3106-3119.
60. Cote, M.; Misasi, J.; Ren, T.; Bruchez, A.; Lee, K.; Filone, C. M.; Hensley, L.; Li, Q.; Ory, D.; Chandran, K. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature, 2011, 477(7364), 344-348.
61. Panchal, R. G.; Reid, S. P.; Tran, J. P.; Bergeron, A. A.; Wells, J.; Kota, K. P.; Aman, J.; Bavari, S. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antiviral Res., 2012, 93(1), 23-29.
62. Opsenica, I.; Burnett, J. C.; Gussio, R.; Opsenica, D.; Todorovic, N.; Lanteri, C. A.; Sciotti, R. J.; Gettayacamin, M.; Basilico, N.; Taramelli, D. A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J. Med. Chem., 2011, 54(5), 1157-1169.
63. Aman, M. J.; Kinch, M. S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res., 2009, 83(3), 245-251.
64. Selaković, Ž.; Opsenica, D.; Eaton, B.; Retterer, C.; Bavari, S.; Burnett, J. C.; Šolaja, B. A.; Panchal, R. G. A Limited Structural Modification Results in a Significantly More Efficacious Diazachrysene-Based Filovirus Inhibitor. Viruses 2012, 4(8), 1279-1288.
65. Modrof, J.; Muhlberger, E.; Klenk, H.-D.; Becker, S. Phosphorylation of VP30 impairs Ebola virus transcription. J. Biol. Chem., 2002, 277(36), 33099-33104.
66. Nekhai, S.; Kovalskyy, D. B. Inhibitors of protein phosphatase-1 and uses thereof. U. S. Patent No. 8, 278, 326, 2012.
67. Johnson, R. F.; McCarthy, S. E.; Godlewski, P. J.; Harty, R. N. Ebola virus VP35-VP40 interaction is sufficient for packaging 3E-5E minigenome RNA into virus-like particles. J. Virol., 2006, 80(11), 5135-5144.
68. Cardenas, W. B.; Loo, Y.-M.; Gale, M.; Hartman, A. L.; Kimberlin, C. R.; Martinez-Sobrido, L.; Saphire, E. O.; Basler, C. F. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol., 2006, 80(11), 5168-5178.
69. Vittori, S.; Dal Ben, D.; Lambertucci, C.; Marucci, G.; Volpini, R.; Cristalli, G. Antiviral properties of deazaadenine nucleoside derivatives. Curr. Med. Chem., 2006, 13(29), 3529-3552.
70. Falzarano, D.; Feldmann, H. Possible leap ahead in filovirus therapeutics. Cell Res., 2014, 24, 647-648.
71. Warren, T. K.; Wells, J.; Panchal, R. G.; Stuthman, K. S.; Garza, N. L.; Van Tongeren, S. A.; Dong, L.; Retterer, C. J.; Eaton, B. P.; Pegoraro, G. Protection against filovirus diseases by a novel broadspectrum nucleoside analogue BCX4430. Nature, 2014, 508(7496), 402-405.
72. Wong, G.; Qiu, X.; Olinger, G. G.; Kobinger, G. P. Post-exposure therapy of filovirus infections. Trends Microbiol, 2014, 22(8), 456-463.
73. Hirschberg, R.; Ward, L. A.; Kilgore, N.; Kurnat, R.; Schiltz, H.; Albrecht, M. T.; Christopher, G. W.; Nuzum, E. Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop. Viruses, 2014, 6(7), 2673-2697.
74. Smither, S. J.; Eastaugh, L. S.; Steward, J. A.; Nelson, M.; Lenk, R. P.; Lever, M. S. Post-exposure efficacy of Oral T-705(Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res., 2014, 104, 153-155.
75. Oestereich, L.; Ludtke, A.; Wurr, S.; Rieger, T.; Munoz-Fontela, C.; Gunther, S. Successful treatment of advanced Ebola virus infection with T-705(favipiravir) in a small animal model. Antiviral Res., 2014, 105, 17-21.
76. Gehring, G.; Rohrmann, K.; Atenchong, N.; Mittler, E.; Becker, S.; Dahlmann, F.; Pohlmann, S.; Vondran, F. W.; David, S.; Manns, M. P. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J. Antimicrob. Chemother., 2014, 69(8), 2123-2131.
77. Hoenen, T.; Groseth, A.; Feldmann, H. Current ebola vaccines. Expert Opin. Biol. Ther., 2012, 12(7), 859-872.
78. Geisbert, T. W.; Young, H. A.; Jahrling, P. B.; Davis, K. J.; Kagan, E.; Hensley, L. E. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis., 2003, 188(11), 1618-1629.
79. Feldmann, H.; Jones, S. M.; Daddario-DiCaprio, K. M.; Geisbert, J. B.; Stroher, U.; Grolla, A.; Bray, M.; Fritz, E. A.; Fernando, L.; Feldmann, F. Effective post-exposure treatment of Ebola infection. PLoS Pathog., 2007, 3(1), e2.
80. Geisbert, T. W.; Daddario-DiCaprio, K. M.; Williams, K. J.; Geisbert, J. B.; Leung, A.; Feldmann, F.; Hensley, L. E.; Feldmann, H.; Jones, S. M. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol., 2008, 82(11), 5664-5668.
81. Bausch, D. G.; Feldmann, H.; Geisbert, T. W.; Bray, M.; Sprecher, A.; Boumandouki, P.; Rollin, P. E.; Roth, C. Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J. Infect. Dis., 2007, 196(Supplement 2), S136-S141.
82. Johansen, L. M.; Brannan, J. M.; Delos, S. E.; Shoemaker, C. J.; Stossel, A.; Lear, C.; Hoffstrom, B. G.; DeWald, L. E.; Schornberg, K. L.; Scully, C. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. Sci. Transl. Med., 2013, 5(190), 190ra79-190ra79.
83. Zhong, Y.; Xu, J.; Li, T.; Yu, X.; Sheng, M. Potential clinical treatment for Ebola pandemic. Sci China Life Sci, 2014, 1-3.
84. Basler, C. F. New Hope in the Search for Ebola Virus Treatments. Immunity, 2014, 41(4), 515-517.
85. Health, U. N. I. O. ClinicalTrials. gov. https://clinicaltrials. gov/ct2/results?term=ebola, (Accessed February 17, 2015).
86. Hayden, F. G. Advances in antivirals for non‐influenza respiratory virus infections. Influenza Other Respir Viruses, 2013, 7(s3), 36-43.
87. Noad, R.; Roy, P. Virus-like particles as immunogens. Trends Microbiol, 2003, 11(9), 438-444.
88. Boisgerault, F.; Moron, G.; Leclerc, C. Virus-like particles: a new family of delivery systems. Expert Rev Vaccines, 2002, 1(1), 101-109.
89. Jahrling, P.; Geisbert, T.; Geisbert, J.; Swearengen, J.; Bray, M.; Jaax, N.; Huggins, J.; LeDuc, J.; Peters, C. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis., 1999, 179(Supplement 1), S224-S234.
90. Jahrling, P.; Geisbert, J.; Swearengen, J.; Jaax, G.; Lewis, T.; Huggins, J.; Schmidt, J.; LeDuc, J.; Peters, C. Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch Virol, 1996, 11, 135-140.
91. Hart, M. K. Vaccine research efforts for filoviruses. Int. J. Parasitol., 2003, 33(5), 583-595.
92. Organization, W. H. Consultation on potential Ebola therapies and vaccines. Geneva, Swizerland. http://www. who. int/mediacentre/events/meetings/2014/ebola-interventions/en/(September 4, 2014).